Agreed... there is a small, but reasonable, probability we could get Accelerated Approval yet this year from the Rett trial. It might not make the price jump over $30 immediately, but we'll start to get more attention, leading to increased share demand that will sustain an impressive rise over time, with PD and Alz on the horizon.
News 
Market Data 
Discover 
